Pharmaceutical - Johnson & Johnson, Gastro-intestinals

Filter

Popular Filters

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Focus on weight-loss drugs in Latin America

23-07-2013

The increasing prevalence of obesity in Brazil and Mexico is encouraging its governments to consider…

Abbott LaboratoriesArena PharmaceuticalsBelviqByettaGastro-intestinalsHealthcareJohnson & JohnsonNovo NordiskPharmaceuticalQsymiaReductilRocheSouth AmericaTopamaxVictozaVivusXenical

Second Genome in deal with Janssen on microbiome drug discovery in ulcerative colitis

06-06-2013

Second Genome has entered into an agreement with Janssen Biotech, a subsidiary of US health care giant…

Gastro-intestinalsJanssenJohnson & JohnsonLicensingPharmaceuticalResearchSecond Genome

US FDA approves Janssen's Simponi to treat ulcerative colitis

16-05-2013

The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Study finds potential use of ustekinumab for Crohn's disease

18-10-2012

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results…

BiotechnologyGastro-intestinalsJanssenJohnson & JohnsonPharmaceuticalResearchStelara Injectionustekinumab

Disappointing FDA views for Bayer's Xarelto and Pozen ulcer drug

22-06-2012

Bayer HealthCare, a unit of Germany's Bayer (BAYN: DE) says that it has received a complete response…

BayerCardio-vascularGastro-intestinalsJohnson & JohnsonNorth AmericaPA32540PharmaceuticalPozenRegulationXarelto

Back to top